Bio-Rad and Bruker Sign a Joint Product Development and Co-marketing Agreement
News Apr 01, 2009
The new products will be based on Bio-Rad's surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker's matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometers for applications of high-throughput protein profiling and identification. The products will provide new solutions for biomarker discovery, in particular, the detection and high-confidence identification of intact peptides and proteins under 30 kilodaltons, which are known to be challenging for currently available technologies to identify.
"We're confident that Bio-Rad's SELDI technology combined with the flexibility delivered by Bruker's TOF/TOF systems will offer tangible benefits to researchers for protein biomarker discovery," said Brad Crutchfield, Bio-Rad Vice President and Life Science Group Manager. "We welcome the opportunity to work with Bruker, a company that, similar to Bio-Rad, has a long history of advancing life science research through its commitment to customer support."
"We are excited about working with Bio-Rad," said Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics. "Bruker Daltonics' high-performance TOF/TOF technology will bring a new dimension to protein profiling and identification, expanding the capabilities of Bio Rad's established SELDI technology. New products based on this combination of technologies will allow access to new technical capabilities and new market segments in applied proteomics, enabling researchers to better identify and characterize new biomarkers."
Missing Link Between Blow Flies and Possible Pathogen TransmissionNews
Determining whether blow flies have consumed animal fecal material versus animal tissue has important implications for both human public health and animal conservation. A recent study shows how that determination can be made.READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE